Progress in systemic therapy for triple-negative breast cancer.
10.1007/s11684-020-0741-5
- Author:
Hongnan MO
1
;
Binghe XU
2
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. xubinghe@csco.org.cn.
- Publication Type:Review
- Keywords:
immunotherapy;
targeted therapy;
triple-negative breast cancer
- MeSH:
Humans;
Immunotherapy;
Molecular Targeted Therapy;
Triple Negative Breast Neoplasms/genetics*
- From:
Frontiers of Medicine
2021;15(1):1-10
- CountryChina
- Language:English
-
Abstract:
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the genetic analysis of TNBC to identify novel targets and increase the precision of therapeutic intervention. Such progress has translated into major advances in treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted therapeutic drugs. All of these strategies have been evaluated in clinical trials. Nevertheless, patient selection remains a considerable challenge in clinical practice.
